Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation.

Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, Fatho M, Lennerz V, Wölfel T, Hölzel M, Tüting T.

Nature. 2012 Oct 18;490(7420):412-6. doi: 10.1038/nature11538. Epub 2012 Oct 10.

PMID:
23051752
2.
3.

[A malignus melanoma immunterápiájának lehetoségei].

Ladányi A.

Magy Onkol. 2003;47(1):113-7. Epub 2003 Apr 18. Review. Hungarian.

4.

Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer.

Clay TM, Custer MC, Spiess PJ, Nishimura MI.

Pathol Oncol Res. 1999;5(1):3-15. Review.

5.

Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?

Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ.

Lancet Oncol. 2012 Jan;13(1):e32-42. doi: 10.1016/S1470-2045(11)70155-3. Review.

PMID:
22225723
6.

Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.

Finn OJ.

Ann Oncol. 2012 Sep;23 Suppl 8:viii6-9. doi: 10.1093/annonc/mds256. Review.

7.

Melanoma as a model tumour for immuno-oncology.

Maio M.

Ann Oncol. 2012 Sep;23 Suppl 8:viii10-4. doi: 10.1093/annonc/mds257. Review.

8.
9.

Trafficking of T cells into tumors.

Slaney CY, Kershaw MH, Darcy PK.

Cancer Res. 2014 Dec 15;74(24):7168-74. doi: 10.1158/0008-5472.CAN-14-2458. Epub 2014 Dec 4. Review.

10.

Current position of TNF-α in melanomagenesis.

Nenu I, Tudor D, Filip AG, Baldea I.

Tumour Biol. 2015 Sep;36(9):6589-602. doi: 10.1007/s13277-015-3639-0. Epub 2015 Aug 18. Review.

PMID:
26279161
11.

Immunosuppression associated with chronic inflammation in the tumor microenvironment.

Wang D, DuBois RN.

Carcinogenesis. 2015 Oct;36(10):1085-93. doi: 10.1093/carcin/bgv123. Epub 2015 Sep 8. Review.

PMID:
26354776
12.

Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment.

Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, Spranger S.

Curr Opin Immunol. 2013 Apr;25(2):268-76. doi: 10.1016/j.coi.2013.02.009. Epub 2013 Apr 8. Review.

PMID:
23579075
13.

Introduction to the role of the immune system in melanoma.

Margolin K.

Hematol Oncol Clin North Am. 2014 Jun;28(3):537-58. doi: 10.1016/j.hoc.2014.02.005. Review.

PMID:
24880946
14.

Tumour immunity: effector response to tumour and role of the microenvironment.

Mantovani A, Romero P, Palucka AK, Marincola FM.

Lancet. 2008 Mar 1;371(9614):771-83. doi: 10.1016/S0140-6736(08)60241-X. Epub 2008 Feb 13. Review.

PMID:
18275997
15.

Inflammation in uveal melanoma.

Bronkhorst IH, Jager MJ.

Eye (Lond). 2013 Feb;27(2):217-23. doi: 10.1038/eye.2012.253. Epub 2012 Dec 14. Review.

16.

T cell exclusion, immune privilege, and the tumor microenvironment.

Joyce JA, Fearon DT.

Science. 2015 Apr 3;348(6230):74-80. doi: 10.1126/science.aaa6204. Review.

PMID:
25838376
17.

Microenvironment and tumor progression of melanoma: new therapeutic prospectives.

Botti G, Cerrone M, Scognamiglio G, Anniciello A, Ascierto PA, Cantile M.

J Immunotoxicol. 2013 Jul-Sep;10(3):235-52. doi: 10.3109/1547691X.2012.723767. Epub 2012 Oct 5. Review.

PMID:
23036080
18.

Cytotoxic T cells - stroma interactions.

Noman MZ, Benlalam H, Hasmim M, Chouaib S.

Bull Cancer. 2011 Feb;98(2):E19-24. doi: 10.1684/bdc.2010.1295. Review.

PMID:
21339092
19.

Focus on skin cancer association and progression under TNF antagonist therapy.

Piérard-Franchimont C, Piérard GE, Quatresooz P.

Expert Opin Biol Ther. 2011 Sep;11(9):1215-22. doi: 10.1517/14712598.2011.582463. Epub 2011 Jul 16. Review.

PMID:
21762036
20.

Immunotherapy of melanoma.

Haanen JB.

EJC Suppl. 2013 Sep;11(2):97-105. doi: 10.1016/j.ejcsup.2013.07.013. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk